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A Non-Targeted LC-MS Profiling 
Reveals Elevated Levels of Carnitine 
Precursors and Trimethylated 
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Pre-Eclamptic Infants
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Seppo Auriola4, Marko Lehtonen4, Kati Hanhineva2, Hannele Laivuori  1,5,6 & FINNPEC*
Preeclampsia (PE) is a complex pregnancy disorder. It is not extensively known how the metabolic 
alterations of PE women contribute to the metabolism of newborn. We applied liquid chromatography-
mass spectrometry (LC-MS) based non-targeted metabolomics to determine whether the metabolic 
profile of plasma from umbilical cord differs between infants born to PE and non-PE pregnancies in 
the FINNPEC study. Cord plasma was available from 42 newborns born from PE and 53 from non-PE 
pregnancies. 133 molecular features differed between PE and non-PE newborns after correction 
for multiple testing. Decreased levels of 4-pyridoxic acid were observed in the cord plasma samples 
of PE newborns when compared to non-PE newborns. Compounds representing following areas 
of metabolism were increased in the cord plasma of PE newborns: urea and creatine metabolism; 
carnitine biosynthesis and acylcarnitines; putrescine metabolites; tryptophan metabolism and 
phosphatidylcholines. To our knowledge, this study is the first one to apply LC-MS based metabolomics 
in cord plasma of PE newborns. We demonstrate that this strategy provides a global picture of the 
widespread metabolic alterations associated with PE and particularly the elevated levels of carnitine 
precursors and trimethylated compounds appear to be associated with PE at birth.
Pre-eclampsia (PE) is a complex metabolic and vascular pregnancy disorder characterized by new-onset hyper-
tension and proteinuria after 20 weeks of gestation, or new-onset PE-associated signs in the absence of pro-
teinuria1. The etiology of PE remains largely unclear, however, defective placentation is frequently present. The 
pathology is also characterized by endothelial dysfunction, metabolic changes, angiogenic imbalance, hypoxia, 
and aberrant immune system2,3. The imminent effects on the fetus include prematurity (due to indicated preterm 
deliveries) and fetal growth impairment4. The metabolic alterations of PE women may also contribute to the 
metabolism of fetus5. However, it is not currently well understood to what extent the metabolic changes observed 
in PE women also affect the newborn.
Metabolomics allows for the concomitant measurement of a wide spectrum of low molecular weight metabo-
lites resulting from endogenous metabolism, dietary intake and gut microbial activity6,7. It has been shown to gen-
erate new insights when investigating physiological status due to disease or treatment and thus, may also provide 
new insights into the pathogenesis of PE. Previously, differential metabolic profiles have been characterized in 
PE across a variety of analytical platforms, in different maternal biospecimens (placenta, blood, serum, urine and 
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amniotic fluid8–13. For instance, changes in lipid and amino acid metabolism and dysregulation of mitochondria 
have been observed. However, relatively scarce data are available on newborns.
In this study, we have taken a non-targeted approach to identify a metabolic signature in cord plasma of 
infants born to PE and non-PE pregnancies in the FINNPEC (Finnish Genetics of Preeclampsia Consortium) 
study in order to elucidate the metabolic changes related to PE.
Methods
Study cohort. The FINNPEC is a cross-sectional case-control multicentre study with a nationwide clinical 
and DNA database on PE and non-PE women, including their partners and newborns. Data of the prospective 
arm was assembled in Finland between 2008 and 2011. Details of the study design, methods and procedures have 
been described elsewhere14. All participants provided written informed consent, and the FINNPEC study pro-
tocol was approved by the coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa. All 
experiments were performed in accordance with relevant guidelines and regulations.
PE was defined as hypertension and proteinuria occurring after 20 weeks gestation according to the American 
College of Obstetricians and Gynecologists (ACOG) 2002 criteria. Cord blood samples were collected after deliv-
ery from a subcohort from the Hospital District of Helsinki and Uusimaa only (n = 486 for the PE newborns and 
n = 526 for the non-PE newborns). For the current LC-MS metabolite profiling analysis, we selected samples of 
newborns whose mothers were non-smoking and from whom we had maternal first and third trimester serum 
samples available (n = 42 for PE newborns and n = 53 for the non-PE newborns, Table 1). After delivery, the 
umbilical cord was double clamped and the cord blood sample was collected in the 10 ml EDTA tubes, centri-
fuged, the plasma was removed and stored at −80 °C.
Non-targeted LC-MS metabolite profiling and identification. The sample preparation, instrument 
parameters and processing of data were performed in the LC–MS Metabolomics Center at Biocenter Kuopio 
(University of Eastern Finland). An aliquot (100 μL) of stored (−80 °C) plasma samples was mixed with 400 μL of 
acetonitrile (ACN; VWR International, Leuven, Belgium), and mixed in vortex at maximum speed 15 s, incubated 
on ice bath for 15 min to precipitate the proteins, and centrifuged at 16 000 × g for 10 min to collect the superna-
tant. The supernatant was filtered through 0.2 μm PTFE filters. Aliquots of 2 μL were taken from at least half of the 
plasma samples, mixed together in one tube, and used as the quality control sample in the analysis. Additionally 
a solvent blank was prepared in the same manner.
The samples were analyzed by the UHPLC-qTOF-MS system (Agilent Technologies, Waldbronn, Karlsruhe, 
Germany) that consisted of a 1290 LC system, a Jetstream electrospray ionization (ESI) source, and a 6540 UHD 
accurate-mass qTOF spectrometer. The samples were analyzed using two different chromatographic techniques, 
i.e. reversed phase (RP) and hydrophilic interaction (Hilic) chromatography. Data were acquired in both positive 
(+) and negative (−) polarity. The sample tray was kept at 4 °C during the analysis. The data acquisition software 
was MassHunter Acquisition B.04.00 (Agilent Technologies). The quality control and the blank samples were 
injected after every 12 samples and also in the beginning of the analysis. The sample order of the analysis was 
randomized. Details on the technical procedures and parameters have been described earlier by Pekkinen et al.15.
Data were collected with “Find by Molecular Feature” algorithm in MassHunter Qualitative Analysis 
B.07.00 software (Agilent Technologies, USA). The extraction algorithm was set to collect peaks with thresh-
old at 200 counts for Hilic and 150 for RP chromatography, and the allowed ion species were [M + H]+, 
[M + Na]+, [M + K]+, [M + NH4]+, and [2M + H]+in ESI(+), and [M−H]−, [M + Cl]−, [M + HCOO]−, 
[M + CF3COO]−, and [2M − H]- in ESI(−). Only signals over compound height threshold of 3000 counts con-
taining at least two ions were included in the compound list. Peak spacing tolerance for isotope grouping was 
0.0025 m/z plus 7 ppm, with isotope model for common organic molecules. Data files (.cef-format) were exported 
to Mass Profiler Professional (Agilent Technologies) for peak alignment. After the first initial alignment, the data 
were combined in one.cef file, against which the original raw data was reanalyzed. For this recursive analysis, 
compound mass tolerance was ±15 ppm, retention time ±0.150 min and symmetric expansion value for chro-
matograms ±35.0 ppm. Resulting compounds were re-exported to Mass Profiler Professional software for peak 
alignment and data cleanup.
Statistical analyses. Statistical analysis of the metabolite profiling data was performed using univariate and 
multivariate analysis methods. For univariate analysis, we calculated p-values (Student’s t-test, α level = 0.05) and 
effects sizes (Cohen’s d = (mean(cases)-mean(controls)/((SD(cases) + SD(controls))/2)) for comparisons between 
PE cases and non-PE controls for each molecular feature. Principal component analysis (PCA) was used to ana-
lyze overall variance within the samples. Because of the correlative nature of molecular features in a metabolite 
profile analysis, we used the number of principal components needed to explain 95% of variance in the data to 
adjust the t-test α level for multiple test correction in the metabolic profiling analysis (Bonferroni’s method). 
Furthermore, we used partial-least-squares discriminant-analysis (PLS-DA) to find out the variables explaining 
most variation between PE and non-PE subjects. For the PLS-DA, variables were normalized by standard devia-
tion (z-score) and mean centered before analysis. Variable importance to the projection (VIP) values are reported 
for each variable. We used the Mass Profiler Professional (MPP) software (Agilent Technologies, version 13) to 
calculate p-values, Microsoft Excel 2016 to calculate Cohen’s d values, and SIMCA (Umetrics, version 14.0.0) 
to perform multivariate analyses. Moreover, we used MS-DIAL ver.2.5216 and MassHunter Qualitative Analysis 
B.07.00 software (Agilent Technologies, USA) for metabolite identification against MSMS spectra found in pub-
lic and in-house standard libraries. In-house database was generated by analyzing commercial and synthetized 
chemical standards in the same analytical conditions using the same instrumentation, and comprised of 634 
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compounds. For public databases, we used Metlin (https://metlin.scripps.edu/, accessed 23.3.2017) and the inter-
nal database found in MS-DIAL (version 2.52).
Figures were made with Prism (GraphPad Software Inc., version 5.03) and SIMCA (Umetrics, version 14.0.0).
Results
Maternal and fetal characteristics are presented in the Table 1. There were no differences in maternal age or body 
mass index (BMI) between the PE and non-PE groups. All women were non-smoking. PE women had elevated 
diastolic and systolic blood pressure and proteinuria as expected according to the diagnostic criteria used for PE. 
The proportion of nulliparous women was higher in the PE group compared with the non-PE group. PE women 
also suffered more from pre-existing diseases (e.g. chronic hypertension, pregestational diabetes and gestational 
diabetes) and had more frequently history of PE compared to non-PE women. PE women had more caesarean 
deliveries than non-PE women. Ten out of 42 PE women received prenatal betamethasone treatment for fetal lung 
maturation. The newborns of PE pregnancies were born earlier and had smaller absolute and relative birth weight 
(Table 1). There was no difference in the sex distribution of newborns.
In the metabolite profiling analysis we observed a total of 2401 molecular features of which 538 had p-values 
below 0.05 (Supplementary Table 1). Urea, indolecarboxylic acid, 2PY, homocitrulline, indolelactic acid, 
1-methylhistidine, creatinine, PC 16:0/16:0, PC 16:0/18:1, and diacetylspermidine were metabolites contributing 
most to the separation of the groups in the PLS-DA (i.e. had the highest VIP-values, Supplementary Table 1). The 
PLS-DA model had five components with cumulative R2Y of 0.96 (percent of variation explained by the model) 
and Q2 of 0.57 (percent of variation predicted by the model according to cross validation). In the PCA analysis, 
total of 77 compounds were needed to explain 95% of the overall variance in the data. This result was used to 
Maternal characteristics Pre-eclampsia (n = 42) Control (n = 53) punadj.
Age at delivery, year 31.3 ± 4.7 (mean ± SD) 30.4 ± 4.6 0.371
Gravidity 1.9 ± 1.2 2.1 ± 1.3 0.407a
Parity 0.3 ± 0.5 0.6 ± 0.7 0.029a
Nulliparous 30 (71.4%) 27 (50.9%) 0.043
Onset of pre-eclampsia (based of delivery)
    Early (≤34 + 0 weeks of gestation) 7 (16.7%) — —
    Late (>34 + 0 weeks of gestation) 35 (83.3%) — —
History of pre-eclampsia 6 (14.3%) 0 (0%) 0.006
Weight, kg (self-reported, pre-pregnancy) 68.8 ± 10.6 70.5 ± 8.9 0.337
Height, m 1.66 ± 0.07 1.67 ± 0.06 0.389
BMI, kg/m2 (self-reported, pre-pregnancy) 25.1 ± 4.0 25.2 ± 2.5 0.644
Systolic blood pressure at first antenatal visit, mm Hg 122 ± 12 115 ± 9 0.003
Diastolic blood pressure at first antenatal visit, mm Hg 79 ± 10 72 ± 7 <0.001
Highest systolic blood pressure, mm Hg 171 ± 17 124 ± 9 <0.001a
Highest diastolic blood pressure, mm Hg 110 ± 9 83 ± 6 <0.001a
Proteinuria (maximum), g/24 hour 4.3 ± 4.2 — —
Chronic hypertension 8 (19.0%) 0 (0%) 0.001
Gestational hypertension — 0 (0%) —
Gestational diabetes mellitus 6 (14.3%) 0 (0%) 0.006
Pregestational diabetes mellitus 4 (9.5%) 0 (0%) 0.035
  Type 1 diabetes 3 (7.1%) 0 (0%) 0.083
  Type 2 diabetes 1 (2.4%) 0 (0%) 0.442
Mode of delivery
  Vaginal 26 (61.9%) 46 (86.7%) 0.005
  Caesarean section 16 (38.1%) 7 (13.2%) 0.005
Prenatal betamethasone treatment 10 (23.8%) 0 (0%) <0.001
Fetal characteristics
Birth weight, g 2866 ± 824 3596 ± 423 <0.001a
Relative birth weight, SD −0.8 ± 1.2 0.0 ± 0.8 <0.001
SGA 3 (7.1%) 0 (0%) 0.083
Gestational weeks 37.0 ± 3.2 39.7 ± 1.3 <0.001a
Sex 0.614
  Male 20 (47.6%) 28 (52.8%)
  Female 22 (52.4%) 25 (47.2%)
Table 1. Maternal and fetal characteristics of the study groups. Chronic hypertension was defined as systolic 
blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg detected before 20 weeks of gestation. 
Gestational hypertension was defined as blood pressure ≥140/90 without proteinuria. SGA = small-for-
gestational age. aNon-parametric test was used.
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adjust the t-test α-level to 0.00065 to account for multiple testing (Bonferroni’s method). This resulted in total of 
133 molecular features which were statistically significantly altered between the umbilical cord plasma of new-
borns of PE and non-PE pregnancies (Fig. 1). The analyses were also re-performed excluding mothers suffering 
from gestational diabetes but only minor changes were observed (analyses not shown).
Compounds related to urea and creatine metabolism (urea, creatine, creatinine, homocitrulline and guan-
idinopropionate) were increased in the cord plasma of newborns of PE pregnancies compared to non-PE cord 
plasma (Fig. 2). Furthermore, metabolites of carnitine biosynthesis and acylcarnitines were increased [carnitine, 
trimethyllysine, gamma-butyrobetaine, butyrylcarnitine, octenoylcarnitine and 5-Amino valeric acid betaine 
(5-AVAB)] in the cord plasma of newborns of PE pregnancies (Fig. 3).
The newborns of PE pregnancies also showed increased levels of N-methyl-2-pyridone-5-carboxamide (2PY). 
Moreover, two putrescine metabolites, acetylputrescine and 4-acetamidobutanoate, were increased in the cord 
plasma of newborns of PE pregnancies. Similarly two metabolites, indolecarboxylic acid and indolelactic acid, 
associated with tryptophan metabolism were increased in the PE newborns. Furthermore, levels of phosphatidyl-
chlolines (PCs) PC(16:1/18:1), PC(16:0/16:0), and PC(16:0/18:1) were increased in the PE newborns compared to 
non-PE newborns. Decreased levels of 4-pyridoxic acid was observed in the cord plasma samples of PE newborns.
The correlations between birth weight, SD, gestational weeks and metabolites are presented in Table 2. The 
strongest negative associations among PE newborns were found between birth weight, gestational weeks and PCs. 
The correlation between PC(16:0/16:0) and birth weight is illustrated in Fig. 4. Table 2 also includes the current 
information available on maternal-fetal transfer and previous literature on the main metabolites detected in the 
study.
Discussion
PE is a complex disorder affecting the health of both mother and newborn. To our knowledge, this study is the 
first one to apply LC-MS based metabolomics to determine whether the metabolic profile of plasma from umbili-
cal cord differs between infants born to PE and non-PE pregnancies. Our data clearly demonstrate that this strat-
egy provides a global picture of the widespread metabolic alterations associated with PE and provides grounds for 
future studies. The main identified changes in PE newborns compared with non-PE newborns included increased 
levels of carnitine precursors and trimethylated compounds. All main findings of identified metabolites are fur-
ther discussed below. However, we are not able to demonstrate whether these or other observed changes are a 
consequence of PE or do they play a role in the pathogenic process itself. They may also represent maternal and/
or fetal compensatory mechanisms e.g. due to oxidative stress.
Carnitine and acylcarnitines. The observed increased levels of carnitine, precursors of carnitine and acyl-
carnitines indicate that the carnitine biosynthesis and mitochondrial β-oxidation processes are altered in the 
PE. Previously, abnormalities of lipid metabolism, particularly impaired fatty acid oxidation, are recognized fea-
tures of PE and are thought to contribute through endothelial dysfunction leading to vascular remodeling and 
Figure 1. Overview of the metabolite profiling results from the cord plasma samples.Total of 2401 molecular 
features were observed from the cord plasma samples. Panel A is showing the first and third component of 
a principal component analysis (PCA). Total of 77 component were needed to cumulatively explain 95% of 
the variance in the data. Panel B shows first two components of a partial-least-squares discriminant-analysis 
(PLS-DA). In the PLS-DA model (B), five components cumulatively explain 96% of the variance in the data 
between the groups. These five components are able to predict 57% of the data (leave-one-out cross-validation). 
Panel C shows the p-values (Student’s t-test), Cohen’s d effect sizes and VIP-values (from PLS-DA) of all 
molecular features. Total of 133 molecular features were significantly altered between newborns of PE and 
non-PE women after correction for multiple testing (adjusted α level = 0.00065, Bonferroni’s correction).
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atherosclerosis17. Very recent findings provide further evidence that the compromised lipid metabolism in PE 
may result from dysfunctional mitochondria8. Previously it has been shown that plasma carnitine concentra-
tions are significantly higher in preterm infants than in term ones and there is a significant negative correlation 
between gestational age and plasma carnitine concentration18. We also observed this association between carni-
tine levels and gestational weeks but only in PE infants.
Figure 2. Metabolites associated with urea cycle and creatine metabolism were increased in cord plasma 
samples of preeclampsia pregnancies. Urea, creatine, creatinine, homocitrulline and guanidinopropionate levels 
were significantly increased in the umbilical cord plasma samples of preeclampsia cases when compared to 
controls. Mean and 95% confidence intervals are show for the groups as well as p-values from t-test.
Figure 3. Trimethylated metabolites were increased in cord plasma samples of preeclampsia pregnancies. 
Increased levels of carnitine, trimethyllysine, butyrobetaine, butyrylcarnitine, octenoylcarnitine, choline and 
5-aminovaleric acid betaine (5-AVAB) were observed in the umbilical cord plasma samples of preeclampsia 
newborns when compared to controls. Trimethyllysine and butyrobetaine are precursors of carnitine. Mean and 
95% confidence intervals are show for the groups as well as p-values from t-test.
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Metabolite
BWT SD GWKs Maternal-fetal 
transfer based 
on human 
studies (yes/no)
Previous literature on 
cord blood/plasma in PEr p r p r p
UREA CYCLE AND CREATINE BIOSYNTHESIS
Urea
All −0.444 <0.001 −0.29 0.004 −0.419 <0.001
Yes51
↑ in umbilical cord blood 
of severe PE cases33
↑ in the amniotic fluid32
PE −0.428 0.005 −0.218 0.172 −0.426 0.005
Non-PE 0.256 0.064 0.099 0.480 0.469 <0.001
Creatine
All −0.293 0.004 −0.146 0.159 −0.331 0.001
Yes52 NAPE −0.169 0.286 0.041 0.796 −0.247 0.115
Non-PE −0.063 0.652 −0.118 0.400 −0.002 0.991
Creatinine
All −0.26 0.011 −0.193 0.061 −0.193 0.061
NA ↑ in the amniotic fluid32PE −0.097 0.541 0.045 0.779 −0.180 0.254
Non-PE −0.058 0.679 −0.112 0.423 0.531 <0.001
Homocitrulline
All 0.295 0.004 −0.138 0.182 −0.339 0.001
NA NAPE −0.087 0.582 0.067 0.674 −0.141 0.374
Non-PE 0.123 0.382 0.063 0.654 0.040 0.774
Guanidinopropionate
All −0.44 0.001 −0.205 0.046 −0.527 <0.001
NA NAPE −0.507 0.001 −0.107 0.501 −0.638 <0.001
Non-PE 0.098 0.485 0.008 0.957 0.085 0.543
CARNITINE, CHOLINE AND BETAINE METABOLISM
Trimethyllysine
All −0.221 0.031 −0.133 0.200 −0.270 0.008
NA NAPE −0.017 0.917 0.149 0.345 −0.128 0.418
Non-PE −0.169 0.228 −0.217 0.119 −0.158 0.259
γ-butyrobetaine
All −0.413 <0.001 −0.183 0.076 −0.508 <0.001
NA NAPE −0.295 0.058 0.021 0.896 −0.555 <0.001
Non-PE −0.124 0.375 −0.173 0.217 0.329 0.016
Carnitine
All −0.434 < 0.001 −0.211 0.04 −0.501 <0.001
Yes22,53,54 ↑ in umbilical vein endothelial cells21PE −0.325 0.036 0.019 0.907 −0.476 0.001
Non-PE −0.212 0.128 −0.297 0.031 −0.017 0.902
Butyrylcarnitine
All −0.516 <0.001 −0.286 0.005 −0.508 <0.001
Yes54,55 ↑ in umbilical vein endothelial cells21PE −0.532 <0.001 −0.215 0.171 −0.555 <0.001
Non-PE 0.030 0.829 −0.092 0.511 0.329 0.016
Octenoylcarnitine
All −0.334 0.001 −0.284 0.005 −0.244 0.017
Yes54,55 ↑ in umbilical vein endothelial cells21PE −0.322 0.038 −0.229 0.145 −0.297 0.056
Non-PE 0.006 0.964 −0.125 0.374 0.374 0.006
Choline
All −0.341 0.001 −0.257 0.012 −0.298 0.003
Yes56 NAPE −0.313 0.044 −0.202 0.199 −0.282 0.071
Non-PE 0.103 0.463 −0.036 0.796 0.294 0.032
5-AVAB
All −0.200 0.052 −0.036 0.732 −0.264 0.010
NA NAPE −0.053 0.737 0.185 0.240 −0.168 0.287
Non-PE 0.048 0.734 −0.066 0.637 0.124 0.374
VITAMIN B6 METABOLISM
4-pyridoxic acid
All 0.266 0.009 0.217 0.035 0.309 0.002
NA NAPE 0.345 0.025 0.316 0.041 0.265 0.090
Non-PE −0.014 0.922 0.008 0.955 0.179 0.199
NICOTINAMIDE METABOLISM
2PY (N-methyl-
2-pyridone-5-
carboxamide)
All −0.426 <0.001 −0.28 0.006 −0.408 <0.001
NA NAPE −0.402 0.008 −0.187 0.235 −0.408 0.007
Non-PE 0.125 0.372 0.008 0.954 0.286 0.038
POLYAMINE METABOLISM
Acetylputrescine
All −0.419 <0.001 −0.109 0.291 −0.577 <0.001
NA NAPE −0.426 0.005 0.022 0.890 −0.627 <0.001
Non-PE 0.069 0.626 0.059 0.673 −0.051 0.717
4-acetamido-butanoate
All −0.088 0.397 0.068 0.510 −0.224 0.029
NA NAPE 0.171 0.280 0.366 0.017 −0.027 0.867
Non-PE 0.025 0.858 −0.021 0.883 −0.070 0.619
TRYPTOPHAN METABOLISM
Continued
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Carnitine is responsible for the transport of lipids from the cytoplasm into the mitochondria for energy 
metabolism. It is made primarily in the liver and kidneys, which are both significantly affected in PE19. Carnitines 
inhibit oxidative stress and prevent lipid peroxidation. Both of these are also important pathological processes 
in PE. Moreover, adequate levels of carnitine are crucial in the neonatal period, since the mitochondrial oxida-
tion of fatty acids is essential for meeting the tremendous energy needs of newborns who have very little stored 
glycogen20.
Previously, Ilsinger et al.21 have shown free carnitine to be higher in the newborns of PE women. They have 
also demonstrated that the concentration of carnitine was higher in the PE newborns than in the maternal sam-
ples. Carnitine supply is thought to be primarily met through placental carnitine uptake from the maternal 
circulation22. Alternatively, higher carnitine levels in infants from PE pregnancies may also result from upregu-
lated fetal or placental biosynthesis23. To our knowledge this is a first study to report elevated levels of carnitine 
Figure 4. Correlation of phosphatidylcholine (PC) 16:0/16:0 and birth weight. Data from non-pre-eclamptic 
(open circles) and pre-eclamptic (closed circles) newborns.
Metabolite
BWT SD GWKs Maternal-fetal 
transfer based 
on human 
studies (yes/no)
Previous literature on 
cord blood/plasma in PEr p r p r p
Indolecarboxylic acid
All −0.385 <0.001 −0.168 0.104 −0.471 <0.001
Yes57 NAPE −0.241 0.124 0.065 0.682 −0.381 0.013
Non-PE 0.103 0.464 0.019 0.890 0.091 0.515
Indolelactic acid
All −0.293 0.004 −0.169 0.102 −0.306 0.003
Yes57 NAPE −0.207 0.188 −0.070 0.662 −0.263 0.093
Non-PE 0.142 0.311 0.094 0.504 0.252 0.069
PHOSPHATIDYLCHOLINES
PC (16:0/16:0)
All −0.664 <0.001 −0.400 <0.001 −0.733 <0.001
NA NAPE −0.688 <0.001 −0.368 0.016 −0.713 <0.001
Non-PE −0.232 0.094 0.137 0.327 −0.415 0.002
PC (16:0/18:1)
All −0.493 <0.001 −0.271 0.008 −0.584 <0.001
NA NAPE −0.54 <0.001 −0.258 0.099 −0.601 <0.001
Non-PE 0.025 0.854 0.035 0.806 −0.178 0.201
PC (16:1/18:1)
All −0.412 <0.001 −0.225 0.028 −0.490 <0.001
NA NAPE −0.347 0.024 −0.098 0.537 −0.441 0.003
Non-PE −0.055 0.697 −0.078 0.581 −0.137 0.327
Table 2. Pearson’s correlation coefficients (r) of metabolites and birth weight (BWT), relative weight (SD) 
and gestational weeks (GWKs) in all study subjects, in PE and non-PE groups. SD= birth weight and height 
converted to standard deviation scores relative to the Finnish references58; NA= data not available.
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precursors (trimethyllysine and gamma-butyrobetaine) in the cord plasma of newborns of PE pregnancy. In addi-
tion to microbiota dependent metabolism from carnitine, gamma-butyrobetaine is also produced endogenously 
from trimethyllysine24. Whether the increased concentrations observed in PE newborns reflect the increased 
need of carnitine or some other mechanism, remain to be elucidated. Currently, the knowledge on the role of 
carnitine precursors in different diseases is sparse. However, elevated serum levels of both gamma-butyrobetaine 
and trimethyllysine are shown to be associated with increased risk of cardiovascular death25. Furthermore, very 
recently Strand et al.26 demonstrated that serum levels of gamma-butyrobetaine and trimethyllysine predict 
long-term risk of type 2 diabetes independently of traditional risk factors, possibly reflecting dysfunctional fatty 
acid metabolism.
In addition to the various carnitine metabolites, we also detected increased levels of other trimethylated com-
pounds, namely choline, glycine betaine and 5-AVAB in the PE pregnancies when compared to the non-PE new-
borns. A recent investigation described a group of trimethylated compounds, including 5-AVAB, to be associated 
with consumption of diets rich in whole-grains27. Furthermore, 5-AVAB has been shown to inhibit carnitine 
transporter OCTN2 dependent intake of L-carnitine in mouse and human cultured cardiomyocytes28,29. OCTN2 
is also responsible for carnitine intake in the placental tissue22. In general the clear increase in various trimeth-
ylated compounds may indicate the fetus’s high demand for choline and methyl donors, as has been suggested 
also earlier30. Previously, the rise in maternal plasma choline concentrations during pregnancy has been shown 
to reflect the mobilization of maternal hepatic choline stores and increase in estrogen. In rats and mouse models 
it has been shown that high choline intake during gestation and early postnatal development improves cognitive 
function in adulthood and prevents age-related memory decline31.
Carnitine has also a role in removing excess toxic metabolites, e.g. acyl groups which are excreted as acylcarni-
tines by the kidneys. We also observed elevated levels of acylcarnitines (buturylcarnitine and octenoylcarnitine). 
Acylcarnitines have been previously investigated in maternal samples as potential biomarkers for PE throughout 
the pregnancy12. Whereas to our knowledge only Illsinger et al.21 has shown that impaired mitochondrial func-
tion and reduced capacity of fatty acid oxidation leads to accumulation of acylcarnitines in the newborns.
Urea cycle. The observed increased levels of urea, creatine, creatinine, homocitrulline and guanidinopro-
pionate in the cord plasma samples of the PE newborns indicate altered function of the urea cycle compared 
to the non-PE newborns. Urea and creatinine levels are known for long to be increased in women with PE32,33. 
Roopnarinesingh et al.32 have also reported elevated levels of urea and creatinine in the amniotic fluid of PE 
women, despite an insignificant increase in urea and creatinine concentrations in maternal and fetal plasma. 
In line with our results, Sharma et al.33 have demonstrated increased urea concentrations in the umbilical cord 
blood of infants born to women with severe PE. Thus, it is possible that these changes in the cord blood reflect a 
derangement in the mechanism required for the elimination of these metabolites from the maternal and/or from 
the fetal compartment.
Phosphatidylcholines (PCs). PCs are glycerophospholipids, where phosphorylcholine moiety occupies a 
glycerol substitution site. They are major component of biological membranes. In previous studies PC content 
in placental tissue of PE-women has been observed to be higher than in placental tissue of non-PE women34. We 
detected PC(16:1/18:1), PC(16:0/16:0), and PC(16:0/18:1) to be increased in cord plasma of PE newborns. 16:0 
most likely represent palmitic acid; 16:1 palmitoleic acid and 18:1 vaccenic acid, elaidic or oleic acid. This may be 
related to the inflammatory response present in PE, since it has been indicated that among acyl-lysophospholipid 
species, lysoPC16:0 and lysoPC18:0 exert the greatest pro-inflammatory activities, such as cytokine secretion35. 
On the other hand, PC(16:0/16:0) is known to have a central role in the function of pulmonary surfactant36.
Lindsay et al.37 have speculated earlier that during normal pregnancy increasing maternal plasma concen-
trations of PCs indicate the enhanced role of phospholipids in non-esterified fatty acids transport to the fetus as 
pregnancy progresses. Whereas Schott et al.38 have stated that PE is a disorder in phospholipid metabolism in 
which malfunctioning of cellular membranes seems to play a major pathogenic role. These alterations could be 
a source of placental pathological changes in PE, such as lipid peroxide insult or dysregulation of lipid transport 
across the syncytiotrophoblast34. A high negative correlations between PCs, birth weight and SD observed in this 
study would strengthen this view.
4-pyridoxic acid. 4-pyridoxic acid is a vitamin B6 catabolite excreted into the urine39. Levels are reported 
to be elevated in renal insufficiency and have a strong, positive correlation with plasma urea and creatinine40. 
Clearances of both 4-pyridoxic acid and creatinine increase during normal pregnancy presumably resulting from 
increased renal perfusion. Thus, we could speculate that the observed decreased concentrations in PE newborns 
may be due impaired maternal renal perfusion. On the other hand, Kliger et al.41 have shown already several 
decades ago that PE (“toxemic”) placentas are characterized by marked pyridoxine deficiency due to lowered 
pyridoxal kinase activity in the placenta as compared with that observed in the normal organ.
2PY. N-methyl-2-pyridone-5-carboxamide (2PY) is a major metabolite of nicotinamide and it has been iden-
tified as a uremic toxin42. To our knowledge, this is first study to report this compound in pregnancy and in PE. 
Previously, it has been shown that the accumulation of 2PY occur in renal failure and might contribute directly 
to the signs and symptoms of uremia43. Thus, one could speculate that the elevated levels observed in the cord 
plasma of PE newborns may be related to the impaired maternal/fetal renal function. Interestingly, 2PY is also an 
inhibitor of the poly(ADP-ribose) polymerase, which is involved in regulation of DNA replication and repair43. 
However, its role in PE remains to be elucidated.
www.nature.com/scientificreports/
9SCIENTIFIC RepoRts |  (2018) 8:14616  | DOI:10.1038/s41598-018-32804-5
Polyamines. We detected two putrescine metabolites, acetylputrescine and 4-acetamidobutanoate to be 
increased in the cord plasma of PE newborns. Putrescine belongs to the group of polyamines which are essential 
for early embryonic development and successful pregnancy outcome44. They exert effects that include stimulation 
of cell division and proliferation, gene expression for the survival of cells, DNA and protein synthesis, regulation 
of apoptosis, oxidative stress, angiogenesis, and cell-cell communication activity44. Their role in PE is very little 
studied. Nitric oxide (NO) and polyamines are both products of L-arginine metabolism and it is thought that the 
L-arginine-NO-polyamine pathway may have a physiological role during pregnancy. To our knowledge, only 
Sooranna et al.45 have measured polyamine concentrations in first trimester and term placentae from normal and 
PE pregnancies, but no difference was observed.
Tryptophan metabolites. We observed levels of two tryptophan metabolites, indolelactic acid and indole-
carboxylic acid to be elevated in the cord plasma of PE newborns. The essential amino acid tryptophan is par-
ticularly important in pregnancy, because of the increased demand for maternal protein synthesis and fetal 
requirements for growth and development46. Previous studies have shown that indoleamine 2,3-dioxygenase 
(IDO), an immunosuppressive enzyme that converts tryptophan to kynurenine, is expressed in the placenta and 
might play a role in the maintenance of pregnancy, although its associations with the pathogenesis of PE remain 
unclear47. Indolecarboxylic acid is a known inhibitor of lipid peroxidation and therefore increased levels observed 
in PE could be associated with the altered mitochondrial function also observed. Indolelactic acid is less studied 
but Morita et al.48 have shown indolelactic acid levels to be higher in umbilical plasma than in maternal plasma 
during normal pregnancy.
Very recently, Gomez-Arango et al.49 studied placental microbiome of pregnant overweight/obese women 
and found that pathways encoding tryptophan were highly enriched. Catabolism of tryptophan in the placenta is 
linked with the establishment and maintenance of the feto-maternal immune tolerance, placental circulation and 
growth and modulation of antimicrobial activity by inhibiting ascending infections from the vagina.
The results obtained from this study demonstrates the complexity of metabolic alterations and value of 
non-targeted metabolomic approach in evaluating the pathophysiology of PE. Although changes in single metab-
olites do not fully represent the underlying process, they provide a basis for further studies. Although it should 
be borne in mind that differences observed e.g. in carnitine metabolism represent multiple metabolites and thus 
systemic alterations could be expected. However, it remains unclear whether these changes are a consequence of 
PE or whether they play a key role in the pathogenic process itself. Furthermore, the changes observed may be due 
to small actual or relative birth weight of the PE newborns. Interestingly, very recently Robinson et al.50 observed 
in line with our results a negative association between birth weight, indolelactic acid and PCs in a population 
based study. The additional effect of PE could be controlled by comparing results with small for gestational age, 
non-PE newborns. However, within this cohort we did not have such control newborns available. One could 
also speculate that feto-placental blood volume condition such as fetal hypovolemic state might have affected the 
results. However, the policies for timing of cord clamping were similar and the umbilical cord blood hemoglobin 
concentrations were within reference value in both groups (data not shown). Thus, we consider that the volume 
distribution does not explain the observed differences in metabolites.
Although the study contains relatively good number of samples, it lacks a validation procedure. In future with 
greater sample size it would be of interest to stratify PE women e.g. by parity, onset of PE or by the delivery mode. 
Moreover, in future it would of interest to explore whether the observed metabolic changes persist into later life 
and reflect the susceptibility to metabolic diseases in later life.
Maternal smoking, an important confounding factor, was an exclusion criteria in the present study. We were 
not able to control for maternal diet, because we did not have sufficient dietary data available to assess the effect. 
Furthermore, betamethasone was used for some of the PE women for the enhancement of fetal lung maturation 
when preterm delivery was imminent. There is possibility that the betamethasone treatment of those PE women 
have affected the metabolome of these infants. Furthermore, one could speculate that six of the PE women who 
suffered also from gestational diabetes may affects the results. Thus, the analyses were also re-performed without 
these mothers but only minor changes were observed (analyses not shown).
In conclusion, we clearly demonstrate that the LC-MS based strategy provides a global picture of the met-
abolic alterations associated with the PE newborns. We particularly observed enhanced carnitine biosynthesis 
and increased concentration of methyl donors. Whether these metabolic changes during early postnatal life are a 
consequence of PE or play a role in the pathogenic process itself remain to be elucidated.
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